Fig. 1From: Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)Study flow. Q2W = every 2 weeks; Q4W = every 4 weeksBack to article page